文献速递心力衰竭与心肌病

射血分数改善的心力衰竭:定义、流行病学与管理

Heart Failure With Improved Ejection Fraction: Definitions, Epidemiology, and Management.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

本文综述射血分数改善的心力衰竭(HFimpEF)这一独立表型,其定义为左室射血分数曾≤40%后改善至>40%。注册研究和临床试验提示其患病率上升,可能与指南导向药物治疗的普及和共识定义演变有关。尽管射血分数恢复,患者仍面临不良结局风险,管理策略仍在积极探索中。

要点

  • HFimpEF定义为左室射血分数曾≤40%后改善至>40%。
  • 患病率上升,与指南导向药物治疗普及和定义演变相关。
  • 射血分数恢复后仍存在不良结局风险,需持续关注。

核心结论

  • HFimpEF是心衰谱系中一个日益被认可的独立表型,尽管射血分数改善,患者仍面临不良结局风险,其长期预后和最佳管理尚不明确。

研究设计与样本

  • 本文为综述,旨在深入评估HFimpEF的流行病学、病理生理学、预后和治疗策略,并指出临床空白和未来研究方向。

主要发现

  • 当代注册研究和临床试验提示HFimpEF患病率上升,可能反映了指南导向药物治疗的更多实施和共识定义的演变。

关键数值与推荐

  • HFimpEF定义为既往左室射血分数≤40%,随后改善至>40%。

临床怎么用

  • 临床中应识别HFimpEF表型,并认识到即使射血分数恢复,患者仍属不良结局高风险人群。

局限性

  • HFimpEF仍相对研究不足,其长期预后和最佳管理存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure with improved ejection fraction (HFimpEF) has gained increasing recognition as a distinct phenotype within the spectrum of heart failure, characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. HFimpEF remains relatively understudied, and uncertainty persists regarding its long-term prognosis and optimal management. Contemporary registries and clinical trials suggest a rising prevalence, likely reflecting both the increased implementation of guideline-directed medical therapy and evolving consensus definitions for its identification. Despite left ventricular ejection fraction recovery, patients with HFimpEF remain at risk for adverse outcomes, and their management remains an area of active investigation. The aim of this review is to provide an in-depth evaluation of HFimpEF, including its epidemiology, pathophysiology, prognosis, and treatment strategies. The authors also highlight existing clinical gaps and propose future research directions to refine risk stratification and therapeutic approaches for this evolving population.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Riccardi, Pabon, Bhatt, et al. Heart Failure With Improved Ejection Fraction: Definitions, Epidemiology, and Management. J Am Coll Cardiol. 2025. PMID: 40533130. doi:10.1016/j.jacc.2025.03.544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。